Drug intelligence / Profile preview

ISM5411

Development stage: Preclinical
Lead developer: InSilico Medicine
Modality: Small Molecules
Administration: Oral

Overview

ISM5411 is a small-molecule inhibitor of the KAT6 (lysine acetyltransferase 6) family of proteins, specifically designed for the treatment of ER+/HER2- breast cancer. Developed by Insilico Medical using its AI-driven drug discovery platform and out-licensed to Menarini, ISM5411 targets the epigenetic regulation of oncogenic pathways. KAT6A and KAT6B are known to co-amplify with the estrogen receptor gene and drive resistance to endocrine therapies. By inhibiting these enzymes, ISM5411 aims to downregulate the expression of ERα and other key drivers of tumor progression, providing a potential therapeutic option for patients with advanced or resistant breast cancer.

Targets

EGLN1 (Prolyl hydroxylase domain-containing protein 2)PHD1 (Prolyl hydroxylase domain-containing protein 1)

Beyond the preview

Go deeper on ISM5411.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ISM5411.

Explore the full profile